Treatment of Psoriasis with Alefacept: Correlation of Clinical Improvement with Reductions of Memory T-Cell Counts

Archives of Dermatology

Volumn 139, Issue 12, 2003, Pages 1563-1570

  Gordon, Kenneth B ^a   Vaishnaw, Akshay K ^b   O'Gorman, John ^b   Haney, Jeff ^c   Menter, Alan ^d  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b BIOGEN   (United States)

^c PFIZER INC   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; METHOTREXATE; PSORALEN; RETINOID;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA SEVERITY INDEX; RANDOMIZED CONTROLLED TRIAL; REMISSION; T LYMPHOCYTE SUBPOPULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COMPUTER GRAPHICS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PSORIASIS; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 0348134794     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.139.12.1563     Document Type: Article

References (25)

1. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest. 1996;98:1878-1887.
2. Gottlieb SL, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995;1:442-447.
3. +) in both normal and diseased human skin. Arch Dermatol Res. 1989;281:24-30.
4. + subsets. J Invest Dermatol. 1998;111:1072-1078.
5. Austin LM, Ozawa M, Kikui T, Walters IB, Krueger JG. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type I cytokines, interferon-γ, interleukin-2, and tumor necrosis factor-α, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol. 1999;113:752-759.
6. Friedri M, Krammig S, Henze M, Döcke WD, Sterry W, Asadullah K. Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch Dermatol Res. 2000;292:519-521.
7. Jeffes EW 3rd, Lee GC, Said S, et al. Elevated numbers of proliferating mononuclear cells in the peripheral blood of psoriatic patients correlate with disease severity. J Invest Dermatol. 1995;105:733-738.
8. + T cells in the blood of psoriasis patients correlates closely with the severity of their disease. Clin Exp Immunol. 2001;126:365-369.
9. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol. 2002;138:657-663.
10. Lebwohl M, Ali S. Treatment of psoriasis, I: topical therapy and phototherapy. J Am Acad Dermatol. 2001;45:487-498.
11. Lebwohl M, Ali S. Treatment of psoriasis, I: systemic therapies. J Am Acad Dermatol. 2001;45:649-661.
12. Wingren AG, Parra E, Varga M, et al. T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit Rev Immunol. 1995;15:235-253.
13. Miller GT, Hochman PS, Meier W, et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med. 1993; 178:211-222.
14. Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses: structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol. 1994;152:2753-2767.
15. Sanders ME, Makgoba MW, Sharrow SO, et al. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-γ production. J Immunol. 1988;140:1401-1407.
16. + T cells is independent of cell activation. Cell Adhes Commun. 1999;7:267-279.
17. Ellis CN, Krueger GG, for the Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 2001;345:248-255.
18. Fredriksson T, Petterson U. Severe psoriasis: oral therapy with a new retinoid. Dermatology. 1978;157:238-244.
19. Ellis C, Krueger G, Shrager D, for the Alefacept Clinical Study Group. Repeated courses of alefacept therapy in chronic plaque psoriasis provide consistent efficacy and safety [abstract]. J Eur Acad Dermatol Venereol. 2001;15(suppl 2): 246. Abstract P24-38.
20. + perivascular dendritic cells. J Invest Dermatol. 1991;96:333-340.
21. Krueger GG, Papp KA, Stough DB, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2002;47: 821-833.
22. Gyulai R, Sugiyama H, Kobayashi S, et al. Alefacept treatment for psoriasis reduces the number of activated T cells in lesional skin and correlates with reduced PASI scores. Poster presented at: International Psoriasis Symposium, European Congress on Psoriasis; June 22, 2001; San Francisco, Calif.
23. +-producing T cells in lesional skin [abstract]. J Invest Dermatol. 2001;117:546. Abstract 938.
24. Sugiyama H, Kobayashi S, Gyulai R, et al. Alefacept inhibits IFNγ production by normal and psoriatic peripheral blood T cells and enhances the action of UVB [abstract]. J Invest Dermatol. 2001;117:465. Abstract 455.
25. + T-cell-directed antibody responses are maintained in psoriatic patients receiving alefacept: results of a randomized study. J Am Acad Dermatol. In press.